Allison Gaw, Michael Mee and Bharat Srinivasa named Partners;
Matthew Rosenberger appointed Partner and Chief Financial Officer;
Promotions reinforce Amplitude’s senior leadership as the firm scales its venture platform in precision medicine and company creation
Montréal, Canada — April 30, 2026 — Amplitude Ventures, Canada’s leading precision medicine venture capital firm, today announced the promotion of four senior team members to Partner, reflecting the firm’s continued commitment to building world-class precision medicine companies and driving meaningful outcomes in patient care. Allison Gaw, Bharat Srinivasa, Michael Mee, and Matthew Rosenberger have been promoted to Partner, with Matthew Rosenberger also assuming the role of Chief Financial Officer.
These promotions recognize the pivotal role each person has played in Amplitude's evolution into a full-stack venture capital platform investing globally in the future of healthcare innovation, partnering with founders and companies to scale quickly and deliver meaningful results for patients.
Allison Gaw, Partner
Allison Gaw joined Amplitude in 2023 as Principal and brings more than 20 years of experience in life sciences business development, strategy, and start-up growth operations. At Amplitude, Allison led the firm’s investment in Evommune (NYSE: EVMN) and, as a board member, guided it through its Series B and C rounds, culminating in a successful $150 million IPO on the New York Stock Exchange in November 2025. Allison has been instrumental in supporting portfolio companies through critical value-inflection milestones and continues to lead new investments, partnering closely with visionary founders to drive strategic thinking.
Bharat Srinivasa, Partner
Bharat Srinivasa is a scientist-entrepreneur and a founding team member of Amplitude. Since 2018, he has been deeply involved in building the firm’s precision medicine platform and company creation engine. Bharat has been instrumental in originating, forming and financing several Amplitude-founded companies including Radiant Biotherapeutics and Reverb Therapeutics. Most recently, Bharat drove Amplitude’s co-led financing of Mediar Therapeutics’ $76 million Series B in January 2026. In addition to his board roles across the portfolio, Bharat leverages his deep expertise in immunology to bridge the gap between breakthrough science and meaningful patient outcomes and is a key architect behind Amplitude’s Antibody 3.0 investment thesis.
Michael Mee, Partner
Michael Mee joined Amplitude in 2019 as Principal, bringing his extensive venture creation experience to accelerate the growth of high-potential precision medicine companies. Michael led Amplitude’s investment in Valence Labs (acquired by Recursion in 2023) and played a pivotal role in the formation of Stereo Biotherapeutics and Rime Therapeutics, the latter of which he currently serves as Chief Executive Officer for. Michael is also the Managing Director at Pre-Amp, Amplitude’s company creation engine, which identifies high unmet need opportunities and builds companies from scratch to address them. Michael continues to lead new investments in next-generation life sciences companies at the intersection of novel science and artificial intelligence while strengthening the output of Amplitude’s unique discovery and venture creation engine.
Matthew Rosenberger, Partner and Chief Financial Officer
Matthew Rosenberger joined Amplitude in 2019 as Vice President, Finance. Bringing an operator-first approach, he built the firm’s financial infrastructure and fund operations from the ground up. He is a key architect of Amplitude’s venture creation strategy, having served as the founding CFO for multiple portfolio companies. Matthew oversees the firm's strategic and operational execution, ensuring the financial discipline required to back world-class entrepreneurs and innovators. In his role as Partner and CFO, he leads all finance, compliance, and LP reporting functions as Amplitude scales its platform and AUM.
“Allison, Bharat, Michael and Matthew each embody Amplitude’s core values — intense scientific curiosity and a deep commitment to building companies, of any stage, to improve patient lives,” said Jean-François Pariseau, Managing Partner of Amplitude Ventures. “Their promotions reflect the depth and breadth of the team we have assembled to accelerate the growth of precision medicine companies across North America and beyond.”
“These key promotions reflect the growth and maturity of our team, from a scrappy, early startup firm to a mature venture capital platform staffed with experienced investors,” added Dion Madsen, Managing Partner of Amplitude Ventures. “Amplitude’s latest announcements recognize the deep bench of experienced operators, investors, and experts we bring to our portfolio companies as they build globally competitive businesses.”
The promotions are effective immediately. Amplitude looks forward to deepening its partnerships with high-potential companies globally.
About Amplitude Ventures
Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with the most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is building world-class companies in precision medicine and next-generation medical devices.
Since 2012, the Amplitude team has deployed a venture growth model to build companies with world-class management teams and scale them to breakout potential. Partnering with founders globally, the team has used this approach to create, build, and grow companies, resulting in over $6 billion in company value. Follow us at @Amplitude Ventures or visit: amplitudevc.com.
Media contact
Karen N. Li
Manager, Marketing and Communications
Amplitude Ventures
.png)
